MSD Wellcome Trust Hilleman Laboratories, India - Case Study
Nov. 26, 2019
Courtesy ofBUCHI
“With the spray drying technology, we have been able to achieve positive outcomes on our flagship vaccine candidate and are planning to extend the technology to other antigens and biopharmaceuticals as well.”
Customer name
Dr. Nitin Saigal, Formulation Scientist
Company / Institution
MSD Wellcome Trust Hilleman Laboratories, India
Product lines
Industries
Customer: MSD Wellcome Trust Hilleman Laboratories, India
A first-of-its-kind initiative, Hilleman Laboratories is an equal joint-venture partnership formed between Merck & Co., a global research-driven pharmaceutical company and Wellcome Trust, a global charitable foundation dedicated to human and animal health. Headquartered in New Delhi, India, Hilleman Laboratories is committed to developing high impact, affordable vaccines for people in developing countries in an innovative and sustainable manner.
Application: Thermostabilization of vaccine products
Spray drying method is used for developing vaccine formulations in stable particulate form. Buchi B-290 is being used for thermostabilization of various vaccine candidates.
Equipment: Mini Spray Dryer B-290 and Dehumidifier B-296
Vaccine candidate/antigen in liquid form is dispersed in solvent(s) with excipients acting as stabilizers (sugars, proteins, amino acids, polymers, surfactants, and plasticizers, as well as charged ions) and the resultant solution is directly spray dried keeping mild to moderate process conditions. This process gives stable vaccine in powder form which can be reconstituted with suitable buffer(s) before administration.
Benefit / Conclusion: Stable vaccine formulation in powder form
Vaccines can be formulated in a stable particulate form by spray drying with acceptable aerodynamic properties. The process removes the water and restricts the biopharmaceutical’s mobility resulting in significantly lowered degradation rate. Spray drying gives a distinct product (in powder form) unlike the traditional lyophilized vaccines available in the market. It is a one step process to increase the stability, temperature tolerance and shelf life of the product. The process of spray drying makes particle engineering more feasible; by manipulating the conditions of the spray-drying process, it is possible to adjust various particle properties such as size distribution, dispersibility, and surface enrichment of biopharmaceuticals. In addition scalability, faster cycle time and lower operational costs gives it a distinct edge over traditional biopharmaceutical technologies.
A first-of-its-kind initiative, Hilleman Laboratories is an equal joint-venture partnership formed between Merck & Co., a global research-driven pharmaceutical company and Wellcome Trust, a global charitable foundation dedicated to human and animal health. Headquartered in New Delhi, India, Hilleman Laboratories is committed to developing high impact, affordable vaccines for people in developing countries in an innovative and sustainable manner.
Application: Thermostabilization of vaccine products
Spray drying method is used for developing vaccine formulations in stable particulate form. Buchi B-290 is being used for thermostabilization of various vaccine candidates.
Equipment: Mini Spray Dryer B-290 and Dehumidifier B-296
Vaccine candidate/antigen in liquid form is dispersed in solvent(s) with excipients acting as stabilizers (sugars, proteins, amino acids, polymers, surfactants, and plasticizers, as well as charged ions) and the resultant solution is directly spray dried keeping mild to moderate process conditions. This process gives stable vaccine in powder form which can be reconstituted with suitable buffer(s) before administration.
Benefit / Conclusion: Stable vaccine formulation in powder form
Vaccines can be formulated in a stable particulate form by spray drying with acceptable aerodynamic properties. The process removes the water and restricts the biopharmaceutical’s mobility resulting in significantly lowered degradation rate. Spray drying gives a distinct product (in powder form) unlike the traditional lyophilized vaccines available in the market. It is a one step process to increase the stability, temperature tolerance and shelf life of the product. The process of spray drying makes particle engineering more feasible; by manipulating the conditions of the spray-drying process, it is possible to adjust various particle properties such as size distribution, dispersibility, and surface enrichment of biopharmaceuticals. In addition scalability, faster cycle time and lower operational costs gives it a distinct edge over traditional biopharmaceutical technologies.
Most popular related searches
Stay in the loop!
Select your areas of interest to receive industry updates.